“Just stay strong and be brave” is 10-year-old Kyrie’s message for children going through tough medical journeys like his. At age 6, Kyrie was diagnosed with a rare soft-tissue cancer called infantile fibrosarcoma. Though chemotherapy is the current standard-of-care, he participated in a Children's Hospital of Philadelphia clinical trial testing the effectiveness of an oral drug with low side effects, called larotrectinib. Theodore Laetsch, MD, principal investigator of CHOP’s Center for Precision Medicine for High-risk Pediatric Cancer, led the initial trials for the medication, which was approved by the FDA in 2018 for a range of cancers with a specific genetic mutation. This remarkable example of precision medicine therapy has changed Kyrie's life, and now his family is sharing his story in a new Cornerstone video. Learn more about the research leading up to the treatment’s development: http://ms.spr.ly/6048sLASI